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a  b  s  t  r  a  c  t
Steroid minimization after kidney transplantation has become more widely practiced as
transplant clinicians seek the potential beneﬁts such as reduced cardiovascular risk factors,
improved growth in pediatric patients, and improved compliance with the immunosuppres-
sion regimen. Steroid avoidance (i.e. no steroids after the ﬁrst week) is generally favored
compared to later withdrawal. Induction therapy is routine in this setting, frequently rabbit
antithymocyte globulin (rATG, Thymoglobulin®) or off-license use of alemtuzumab. Direct
comparisons of steroid minimization regimens versus standard steroid regimens are rare.
However, the available data show that the risk of acute rejection is low when rATG or
alemtuzumab induction is given to support steroid-avoidance regimens after kidney trans-
plantation. Steroid avoidance may be inadvisable in patients at high immunological risk or
at  risk of recurrent glomerular disease. Steroid withdrawal after day 8 may be possible with-TG
abbit antithymocyte globulin
hymoglobulin
lemtuzumab
out  additional risk of rejection in patients given rATG induction, but while encouraging, the
data are too sparse for ﬁrm conclusions. In summary, steroid avoidance may be beneﬁcial
for  patients after renal transplantation, with the potential to avoid or reduce steroid-related
Abbreviations: ANZDATA, Australia and New Zealand Dialysis and Transplant Registry; BPAR, biopsy-proven acute rejection; CI, conﬁ-
ence  interval; CNI, calcineurin inhibitor; CsA, cyclosporine; DSA, donor-speciﬁc antibody; HR, hazard ratio; IL-2R, interleukin 2 receptor;
DIGO, the Kidney Disease: Improving Global Outcomes; MMF, mycophenolate mofetil; NODAT, new-onset diabetes mellitus; OPTN, Organ
rocurement and Transplantation Network; PRA, panel reactive antibodies; rATG, rabbit antithymocyte globulin.
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comorbidities. Whilst depleting induction therapy could be the treatment of choice, results
of  prospective randomized, controlled studies are eagerly awaited.
©  2016 Sociedad Espan˜ola de Nefrologı´a. Published by Elsevier Espan˜a, S.L.U. This is an
open  access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
Inducción  con  anticuerpos  antilinfocitarios  y  minimización  de  esteroides
en  trasplante  renal
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Trasplante renal
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r  e  s  u  m  e  n
La minimización de esteroides después del trasplante renal constituye una práctica muy
extendida en la búsqueda de potenciales beneﬁcios cardiovasculares, mejor crecimiento
en  pacientes pediátricos o aumento de la adherencia al tratamiento inmunosupresor. El
uso  de inducción depletiva con ATG de conejo o alemtuzumab puede contribuir a evitar
el  uso de esteroides o, al menos, a permitir su suspensión precoz. Esta estrategia se ha
revisado en la literatura, an˜adiendo la opinión de expertos al análisis. La suspensión de
esteroides muy precoz (antes de la primera semana) parece preferirse a la suspensión más
tardía. En ese contexto, la inducción preventiva es la práctica más  utilizada, habitualmente
con  globulina antitimocítica de conejo (rATG, timoglobulina) o alemtuzumab (en uso fuera
de  indicación). Son raras las comparaciones directas de los regímenes de minimización de
esteroides con los de uso estándar. Sin embargo, los datos disponibles muestran que el
riesgo de rechazo agudo es bajo cuando se administra rATG o alemtuzumab para facilitar
la  suspensión muy precoz de esteroides. Esta práctica puede ser menos aconsejable en
pacientes con alto riesgo inmunológico o predispuestos a una recurrencia de la enfermedad
glomerular de base. La suspensión de esteroides a partir del día 8 es factible sin que el
riesgo de rechazo aumente en pacientes tratados con rATG. No obstante, y aunque los datos
disponibles así lo indican, requieren conﬁrmación deﬁnitiva. En conclusión, la minimización
extrema de esteroides puede ser beneﬁciosa en pacientes que reciben un trasplante renal,
con  la ventaja que supone evitar o reducir la comorbilidad asociada con ese tratamiento.
Si  bien la inducción depletiva podría ser el tratamiento de elección en ese contexto, son
necesarios nuevos ensayos aleatorizados controlados que lo conﬁrmen.
© 2016 Sociedad Espan˜ola de Nefrologı´a. Publicado por Elsevier Espan˜a, S.L.U. Este es un
artı´culo Open Access bajo la licencia CC BY-NC-ND (http://creativecommons.org/licenses/
by-nc-nd/4.0/).Introduction
Steroid-sparing immunosuppressive regimens are widely
used after kidney transplantation as clinicians seek to
minimize steroid-related adverse events.1 Rapid steroid dis-
continuation lowers the rates of cataracts, vascular necrosis
and cytomegalovirus infection2 and may improve growth in
children.3 Cardiovascular beneﬁts are less well established,
although positive effects have been observed for lipid pro-
ﬁle and weight gain.4,5 Generally, it is difﬁcult to demonstrate
differences in randomized trials in unselected populations,
and studies of steroid minimization regimens have often not
reported steroid-related side effects, or were underpowered
to demonstrate a signiﬁcant difference. However, even if data
remain unconvincing about reduced cardiovascular risk, the
non-cardiovascular side effects of chronic steroid therapy
require costly management6 and some, such as weight gain,
can adversely affect patient compliance7,8 with potential con-
sequences for graft outcomes.Strategies for steroid minimization comprise either ‘steroid
avoidance’ (or ‘steroid-free’) regimens, which will be deﬁned here
as no intravenous (i.v.) or oral steroids after the ﬁrst 1–2 weeks
post-transplant, or steroid withdrawal, i.e. steroid discontinua-
tion after weeks 1–2.4,9,10
Steroid avoidance protocols have become increasingly pop-
ular in recent years. Steroid-free immunosuppression without
induction therapy has been attempted after kidney transplan-
tation using a calcineurin inhibitor (CNI)-based maintenance
regimen, but randomized trials showed acute rejection to be
signiﬁcantly more  frequent4,11,12 or more  severe13 than with
standard steroids. A series of randomized trials comparing
steroid avoidance versus ongoing steroid therapy in selected
populations receiving interleukin-2 receptor (IL-2R) induction
have reported mixed results.14–18 High rates of biopsy-proven
acute rejection (BPAR) were observed in the FREEDOM study
for patients given basiliximab induction with cyclosporine
(CsA), mycophenolic acid (MPA) and either a single i.v. dose
of steroids (31.5% BPAR at 1 year) or steroids to day 7 (26.1%).19
Other researchers have found no signiﬁcant effect on BPAR
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sing steroid avoidance with IL-2R antagonist induction, espe-
ially with concomitant tacrolimus,15,16 although BPAR may
ccur earlier.16
Many  centers, particularly in the US, instead employ
ymphocyte-depleting induction when steroid-free therapy is
lanned, an approach that may be partly based on experience
rom conventional immunosuppressive regimens. Random-
zed trials of patients at low or moderate immunological
isk given standard steroids have shown comparable rejec-
ion rates using induction with an IL-2R antagonist or rabbit
ntithymocyte globulin (rATG),19–22 but for high-immunologic
isk populations both the overall rejection rate and the inci-
ence of steroid-resistant rejection is lower with rATG.23,24
his may have encouraged more  frequent selection of rATG
r another depleting agent when attempting steroid avoid-
nce: almost 90% of kidney transplantation patients who are
ischarged on a steroid-free regimen in the US receive a
ymphocyte-depleting induction agent,25 with the remaining
0% given IL-2R antagonist induction.
Steroid withdrawal after the ﬁrst week post-transplant
ends to be regarded with more  caution. A meta-analysis
f eight randomized trials found that steroid withdrawal
fter week 1 signiﬁcantly increased both acute rejection
nd graft loss.26 In a further meta-analysis, in which only
hose trials that included CNI therapy with mycophenolate
ofetil (MMF)  were analyzed, graft loss was minimized, but
he risk of acute rejection was still higher following steroid
ithdrawal.27 The Kidney Disease: Improving Global Out-
omes (KDIGO) recommendations suggest that in low-risk
atients given induction therapy, steroids can be discontinued
uring week 1.28 If steroids are administered beyond the ﬁrst
eek post-transplant, however, KDIGO suggests that they be
aintained thereafter.28 This may, however, be an oversimpli-
cation. A recent Cochrane systematic review concluded that
lthough late (month 3–6) steroid withdrawal is associated
ith increased rejection rates in CsA-treated patients (risk
atio 1.61, p = 0.0018), this does not appear to be the case when
acrolimus is given with MMF  (risk ratio 0.82, p = 0.29).9,10,29,30
qually, the safety of steroid withdrawal may be affected by
he choice of induction therapy.
This article reviews the evidence relating to lymphocyte-
epleting induction with rATG or alemtuzumab to support
teroid avoidance or withdrawal in kidney transplant recip-
ents. It should be borne in mind that alemtuzumab in solid
rgan transplantation is used off-label, and the indication is
ot likely to be forthcoming.
ymphocyte-depleting  induction  and
teroid-free  immunosuppression
ATG  induction
andomized trials relating to steroid-free treatment of kid-
ey transplant patients given rATG induction are relatively
are, with only sparse data directly comparing steroid-free
herapy versus standard steroids (Table 1). One may deduce,
owever, that steroid-free immunosuppression is safe, as
hown in trials such as the one published in 2005 by Kan-
aswamy et al.31 In that study, 239 ﬁrst or second kidney(5):469–480 471
transplant recipients all received rATG (1.25–1.5 mg/kg for ﬁve
doses) with a single dose of i.v. steroids then oral steroids
to day 5.31 The trial did not compare steroid-free with
steroid conventional therapy: instead, all patients received
the very short ﬁve-day steroid regimen. They were random-
ized to one of three maintenance regimens: CsA with MMF,
high tacrolimus (trough level 8–12 ng/mL) with low sirolimus
(3–7 ng/mL), or low tacrolimus (3–7 ng/mL) with high sirolimus
(8–12 ng/mL), and followed to month 24. Rates of BPAR were
low and similar in all groups (4–6%); graft and patient sur-
vival was also excellent (Table 1). At month 24, 75%, 90% and
83% of patients, respectively, remained steroid-free, and the
incidence of steroid-related events (post-lymphoproliferative
disease, new-onset diabetes mellitus [NODAT], osteonecro-
sis and viral infection) was encouragingly low. There were
no major differences in complications between groups, other
than a higher rate of wound healing complications in the high
sirolimus arm (p = 0.02).31 These results suggest that any of
these steroid-free maintenance protocols is effective when
given with rATG induction, even in an unselected cohort of
patients.
One randomized trial that compared rATG induction with
or without ongoing steroids was a 12-month single-center
study in 60 ﬁrst or second kidney transplant recipients.32
In fact, what made this trial unique is that it compared
steroid-free versus standard steroids as the single varia-
tion between the comparative arms. The rATG dose was
1 mg/kg, for three to ﬁve doses, with a seven-day course of
i.v. steroids. Patients received tacrolimus with MMF,  with or
without oral steroids. Graft function and rates of clinical rejec-
tion (13% versus 11% in controls) were unaffected by the
absence of steroid therapy. Protocol biopsies were undertaken
in 19 patients at month 12, and although subclinical rejec-
tion rates were similar in both arms, the increase in ﬁbrosis
at 6 and especially at 12 months was signiﬁcantly greater in
the steroid-avoidance group (p < 0.001), a potential cause for
concern although in most patients ﬁbrosis was mild (grade
1). Assessment of subclinical changes by protocol biopsies
may be an important focus in future studies of steroid avoid-
ance.
Woodle et al. undertook a multicenter, randomized trial
in which 151 living-donor kidney transplant patients were
given either rATG (1.25–1.5 mg/kg for four days) with steroids
discontinued by day 6, or to no induction with standard i.v.
and oral steroids until at least month 3 post-transplant.5 All
patients were given tacrolimus and MMF, and dosing was
similar in both treatment groups. By month 12, 72% of rATG-
treated patients remained steroid-free, while in the control
arm only 12% of patients managed to stop steroids. The
12-month incidence of BPAR was 13.9% versus 19.4% for the
rATG/steroid-free group versus the control arm (n.s.) (Fig. 1).
In terms of steroid-related adverse events, levels of total
cholesterol was signiﬁcantly lower in the steroid-free group
at 12 months post-transplant, with a trend to less weight gain
(p = 0.07).5
Other randomized trials have employed different rATG
regimens with various maintenance protocols.33–35 Each of
these has shown good graft and patient survival rates, with
no indication of increased rejection when steroid avoidance is
supported by rATG induction (Table 1).
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Table 1 – Randomized trials of rATG or alemtuzumab induction with steroid avoidance in kidney transplantation.
Study Risk status, N Study
duration
rATG Steroids Maintenance BPAR (%) Graft/ patient
survival (%)a
rATG induction
Kandaswamy31
Single center
Unselected
N  = 239
2Y 1.25–1.5 mg/kg × 5 i.v. + oral to day 5 CsA, MMF 6 95/98
High TAC
Low SRL
4  94/97
Low TAC
High SRL
5 96/97
Laftavi32
Single center
Moderate/low
N  = 60
12M 1  mg/kg × 3–5 i.v. + oral to day 7 TAC, MMF 13 –
i.v. + oral ongoing 11 –
Stevens33
Single center
Moderate/low
N  = 180
6M 6  mg/kg × 1 i.v. only (<7 days) TAC/SRL or
MMF/SRL
8 100/100
1.5 mg × 4 12 98.6/96
Ciancio34
Single center
Unselected
N  = 150
12M 1  mg/kg × 3 +
daclizumab
1 mg/kg × 2
i.v. + oral (<7 days) TAC, MMF 3 97/100
TAC,
EC-MPS
9 96/99
Woodle5
Multicenter
Living donor
Moderate/low
N = 151
12M 1.25–1.5 mg/kg × 4 i.v. + oral (<7 days) TAC, MMF 13.9 98.1/100
No rATG i.v. + oral ≥ 3M 19.4 97.9/100
Grafals35
Single center
Low
N  = 45
12M 0.75  mg/kg × 3 i.v.  + oral (<7 days) TAC, MMF 10 85/85
1.24 mg/kg × 3 17  100/100
Alemtuzumab induction
Vathsala36
Multicenter
Moderate/low
N = 30
6M ALEM 20 mg × 2 i.v. × 1 Reduced
CSA
25 85/95
None Standard CSA, AZA 20 100/100
Margreiter37
Multicenter
Moderate/low
N = 131
12M ALEM 20 mg × 2 i.v. × 2 Delayed
TAC
20 96/98
None Standard TAC, MMF 32 90/98
Chan38
Single center
Unselected
N  = 123
24M ALEM 30 mg × 1 i.v. + oral to day 7 TAC 11.1 97.6/100
DAC 2 mg/kg × 3 TAC, MMF 17.7 95.1/97.5
Welberry Smith39
Single center
Moderate/low
N  = 116
12M ALEM 30 mg × 1 i.v. × 1 TAC 10.3 94.9/96.6
BAS 20 mg × 2 TAC, MMF 24.1b 94.8/96.6
3C Study Group
Multicenter40
Unselected (4%
sensitized)
N = 852
6M ALEM 30 mg × 2 None Reduced
TAC
Reduced
MMF
7  96/97
BAS 20 mg × 2 Oral (ongoing) TAC, MMF 16c 97/99
ALEM, alemtuzumab; AZA, azathioprine; BAS, basiliximab; BPAR, biopsy-proven acute rejection; CsA, cyclosporine; DAC, daclizumab; EC-MPS,
enteric-coated mycophenolate sodium; i.v., intravenous; MMF, mycophenolate mofetil; rATG, rabbit antithymocyte globulin; SRL, sirolimus;
TAC, tacrolimus.
a At end of study (see study duration in column 3).
b p = 0.049.
c p < 0.0001.
Whether early steroid withdrawal after rATG induction
could lead to an increased risk of donor-speciﬁc antibody
(DSA) development was ﬁrst studied by Delgado et al.41 in
low-immunologic risk kidney transplant recipients. In this
longitudinal study, performed in 37 patients randomized to
early corticosteroid withdrawal at day 7 post-transplant (n = 21
patients), or to maintenance steroid therapy (n = 16) – with all
patients receiving rATG induction – there was no difference
between the two groups in terms of DSA development during
ﬁve years’ follow-up. Interestingly, only one patient devel-
oped DSA (in the control group). This is fewer than would be
expected, suggesting a protective role for rATG in DSA occur-
rence. Supportive data were recently published in a study by
Brokhof et al.42 undertaken in a population of 114 consecutive
moderately sensitized recipients who  were divided into two
groups based on induction immunosuppression (rATG versus
basiliximab). At month 36 post-transplant, there was a lower
incidence of de novo DSA and antibody-mediated rejection in
the rATG group when compared with basiliximab. However,in this study standard maintenance steroids were given to all
patients.
Alemtuzumab  induction
Several randomized trials of steroid-free therapy have
employed alemtuzumab induction, at a dose of 30 mg  given
either once or twice (Table 1). Vathsala et al. performed a
small, six-month study in which 30 patients were randomized
to alemtuzumab with reduced-exposure CsA monotherapy
and no oral steroids or to no induction with a conventional
CsA-based regimen with steroids and azathioprine.36 Graft
survival was 85% at month 6 in the alemtuzumab group
versus 100% in the control arm, but larger studies of alem-
tuzumab with reduced-CNI,37 delayed CNI37 or tacrolimus
monotherapy38,39 have not shown any deleterious effect on
graft survival when alemtuzumab has been used to sup-
port steroid avoidance (Table 1). Consistently, the incidence
of BPAR at 12 months post-transplant has been lower with
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Fig. 1 – Freedom from biopsy-proven acute rejection (BPAR),
in moderate- or low-risk living donor kidney transplant
patients randomized to rabbit antithymocyte globulin
(rATG) with intravenous steroids only, or to no steroids
with intravenous steroids and oral steroids for ≥3 months,
both with tacrolimus (TAC) and mycophenolate mofetil
(MMF)  (Kaplan–Meier estimates). No statistical analysis was
provided (observed rates of BPAR: 13.9% for rATG/TAC/MMF
versus 19.4% for TAC/MMF/steroids; p = NS).
Reproduced with permission from.5
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Fig. 2 – Incidence of biopsy-proven acute rejection (BPAR) in
852 unselected kidney transplant patents randomized to
alemtuzumab induction with low-exposure tacrolimus,
low-dose mycophenolic acid and no steroids, or to
basiliximab induction with standard tacrolimus, standard
mycophenolic acid and standard steroids. HR,  hazard ratio;
CI, conﬁdence interval.
40
to address the risk of selection bias. Within the subpopulationlemtuzumab induction, a reduced-intensity maintenance
egimen and a steroid-free protocol versus conventional regi-
ens with36,37,40 or without38,39 steroids.
The largest trial in this series is the 3C study.40 A total of
52 patients were randomized to alemtuzumab (30 mg  peri-
peratively and on the subsequent day) with low-exposure
acrolimus (5–7 ng/mL) and reduced-dose MPA (enteric-coated
ycophenolic acid 360 mg  b.i.d.), or to a conventional regimen
f basiliximab induction, tacrolimus (5–12 ng/mL), standard
PA dosing (540–720 mg  b.i.d.) with ongoing oral steroids. Dur-
ng the ﬁrst six months post-transplant, the risk of BPAR was
igniﬁcantly lower in the alemtuzumab group versus controls
Fig. 2). The difference arose during the early weeks after trans-
lantation and was accounted for by a reduced rate of T-cell
ediated rejection (hazard ratio [HR] 0.37; 95% conﬁdence
nterval [CI] 0.23–0.58; p < 0.0001); antibody-mediated rejection
as similar in both treatment arms (HR 1.59; 95% CI 0.52–4.86;
 = 0.41).40 Graft and patient survival rates at month 6 were
imilar between groups. Leukopenia was signiﬁcantly more
requent under alemtuzumab, as would be expected, but there
as no between-group difference in opportunistic infections
r serious infections. Longer-term follow-up from this trial will
e of interest, since at month 6 patients were randomized to
emain on tacrolimus or switch to sirolimus. Reconstitution of
he lymphocyte population after recovery from alemtuzumab-
nduced depletion may on one hand have profound effects on
he risk of graft rejection, or on the other hand may give rise to
ore tolerogenic lymphocyte subsets. One recent retrospec-
ive study of 200 consecutive non-sensitized kidney transplant
atients treated with rapid steroid taper reported that as well
s higher rates of acute rejection, three-year graft survival was
ower under alemtuzumab induction versus rATG.43Reproduced with permission from.
No randomized trial of alemtuzumab with steroid avoid-
ance after kidney transplantation has shown reduced patient
survival when followed for up to two years,36–40 an important
point in view of the severe lymphocyte depletion associated
with alemtuzumab and the potential risk for infectious deaths
or malignancy.
Comparative  studies  between  induction  agents  within
steroid-free  regimens
Two registry analyses have speciﬁcally assessed outcomes
according to type of induction in kidney transplant patients
discharged on a steroid-free regimen.25,44 Sureshkumar et al.
analyzed Organ Transplantation and Procurement Network
(OPTN) data from 9172 patients who received a deceased-
donor kidney transplant during 2000–2008, with a median
follow-up of 26.8 months.25 The risk of graft failure after
adjustment for a range of potentially confounding variables
was found to be signiﬁcantly higher with alemtuzumab or
IL-2R antagonist induction compared to rATG (Fig. 3). Fur-
ther analyses showed that higher graft survival for rATG
versus alemtuzumab was maintained in at-risk populations
(sensitized patients [panel reactive antibodies (PRA) > 20%],
expanded criteria donor recipients and cold ischemia time
>24 h)23 but signiﬁcance was lost in these subpopulations for
the comparison between rATG and IL-2R antagonists. Data on
rejection were not reported, so it is unclear whether differ-
ences in graft failure were related to a lower propensity to
rejection under rATG or other causes of graft loss. In a more
recent cohort (2000–2012) of patients registered with OPTN,
Tanriover et al. analyzed lower-risk living-donor recipients of
a ﬁrst transplant who were discharged on tacrolimus and MMF,
with or without steroid therapy.44 Propensity scoring was usedthat was discharged steroid-free (n = 10,157), acute rejection at
one year post-transplant was signiﬁcantly lower with either
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variables in deceased-donor kidney transplants performed
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and Transplantation Network (OPTN) who  were  discharged
on steroid-free immunosuppression. HR, hazard ratio; CI,
conﬁdence interval; rATG, rabbit antithymocyte globulin;
IL-2R, interleukin-2 receptor.
the end of month 5 post-transplant.49 All patients receivedReproduced with permission.25
rATG (odds ratio 0.73; 95% CI 0.59–0.90) or alemtuzumab (0.53;
0.42–0.67) versus IL-2R antagonist induction. The one-year risk
of graft failure was higher with alemtuzumab versus IL-2R
antagonist induction (odds ratio 1.27; 95% CI 1.03–1.56) but
similar for rATG versus IL-2RA antagonists (1.19; 0.97–1.45).
Randomized trials comparing steroid avoidance with dif-
ferent induction regimens are relatively rare (Table 2). In a
double-blind, placebo-controlled trial of steroid cessation at
seven days versus ongoing steroids, both with tacrolimus
and MMF,  the 191 patients in the steroid-withdrawal group
received either rATG (n = 125) or an IL-2R antagonist induc-
tion (n = 66).46 In this subpopulation, the ﬁve-year incidence
of BPAR was 14.4% versus 24.2%, respectively (p = 0.09). Results
of the ongoing SAILOR study, comparing rATG with steroid
avoidance versus IL-2R antagonist induction with standard
oral steroids in patients receiving low-dose tacrolimus and
concentration-controlled MMF,50 will help to clarify the rela-
tive effectiveness of each class of agent in preventing rejection
in the absence of steroids.
In a large trial of kidney transplant patients stratiﬁed as
either high or low immunological risk, Hanaway et al. ran-
domized a 139 high-risk cohort to alemtuzumab or rATG, and
335 low-risk patients to alemtuzumab or basiliximab, all with
tacrolimus and MMF;  steroids were discontinued by day 5.46
In the high-risk group, there was no difference in the rate
of BPAR between alemtuzumab and rATG at year 3 (Table 2).
For low-risk patients, however, alemtuzumab induction was
associated with a reduced rate of BPAR versus basiliximab
(10% versus 22%, p < 0.001). A further comparison of alem-
tuzumab versus rATG will be provided by the BEST study,
an ongoing randomized, open-label trial in which patients3  6(5):469–480
receive belatacept-based immunosuppression with MPA and
early steroid withdrawal, using induction with alemtuzumab
in one group and rATG in a second group, or tacrolimus, MPA,
early steroid withdrawal and rATG induction (NCT01729494).
Ciancio et al. undertook a randomized, single-center study
of combined induction protocols in 200 ﬁrst kidney transplant
patients, whereby rATG was combined with either daclizumab
or with a single dose of alemtuzumab47 (Table 2). All patients
were given oral steroids to day 7, with maintenance ther-
apy comprising tacrolimus and MPA. As might be expected
with this relatively intensive regimen, rates of BPAR were
low in both groups (10% and 9%), although graft survival
was numerically higher in the rATG/daclizumab arm (91%
versus 83%, n.s.). Early leukopenia was more  frequent than
with rATG/alemtuzumab induction, despite reduced MPA dos-
ing, than with rATG/daclizumab (12% versus 31%, p = 0.002).47
Other comparative studies of rATG versus alemtuzumab or
an IL-2R antagonist using steroid-avoidance regimens have
usually been relatively small (<40 patients), with different
maintenance protocols and steroid use between treatment
arms, limiting interpretation48,49 (Table 2). One notable point
was a high rate of BPAR (21.4% at month 12) in a small series of
kidney-pancreas patients randomized to alemtuzumab with
tacrolimus monotherapy and no oral steroids,48 but conﬁrma-
tory data are lacking.
Three randomized trials of alemtuzumab with steroid
avoidance have used an IL-2R antagonist in the control arm, as
discussed above, but since the maintenance regimen differed
between groups the effect of the induction regimen cannot be
assessed.38–40
Lymphocyte-depleting  induction  and  steroid
withdrawal
So far, head-to-head comparisons of steroid withdrawal with
or without lymphocyte-depleting induction therapy have not
been undertaken. Typically, studies of steroid withdrawal
either before or after the ﬁrst year post-transplant have not
included induction therapy.4,9,10
One large study of late (month 3) steroid withdrawal
allowed lymphocyte-depleting induction according to local
practice. A third of patients (34% and 33% in the steroid-
withdrawal and control groups, respectively) received induc-
tion, but this included both rATG and monomurab (OKT3).51 In
this subgroup of 169 patients, the 12-month incidence of BPAR
was 14% without steroids compared to 17% in the steroids
group, i.e. steroid withdrawal was successfully achieved. In
contrast, for the 331 patients without any induction ther-
apy, BPAR was higher in the steroid-withdrawal patients (29%
versus 15% in controls). Although only a subanalysis, these
data suggest an advantage for lymphocyte depleting induction
when undertaking steroid withdrawal after kidney transplan-
tation.
In the SPIESSER study, 150 moderate-risk or low-risk kid-
ney transplant patients underwent steroid withdrawal atrATG induction.52 The intervention group was randomized to
sirolimus and MMF in a CNI-free regimen, while the control
group received CsA and MMF. In both arms, the 12-month
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Table 2 – Randomized comparative trials of induction therapy with steroid avoidance in kidney transplantation.
Study Risk status, N Study duration Induction Steroids Maintenance BPAR
(%)
Graft/patient
survival (%)a
Woodle45
Multicenter
Low  or moderate
N = 191
5Y rATG  1.5 mg/kg × 4 i.v./oral to
day 7
TAC 14.4 –
IL-2RAb MMF 24.2 –
Hanaway46 High
N = 139
3Y Alemtuzumab
30  mg × 1
Steroids ≤5
days
TAC MMF 18 99
rATG 1.5 mg/kg × 4 15 91
Low
N = 335
Alemtuzumab
30  mg × 1
10c 95
BAS 20 mg × 2 22c 98
Ciancio47
Single center
Unselected
N = 200
Median 38 M rATG
1  mg/kg × 3 + DAC
1 mg/kg × 2
i.v. × 3 ± oral
(<day 7)
Reduced TAC
EC-MPS
10 91/96 (4
years)
rATG
1 mg/kg × 1 + ALEM
0.3 mg/kg × 1
Reduced TAC
50% EC-MPS
9  83/92 (4
years)
Bösmüller48
Single center
Kidney-pancreas
N = 30
12M ALEM 30 mg × 1 i.v. × 1 TAC 21.4 92.8/100
rATG 4 mg/kg × 1 or
ATG-F 8 mg/kg × 1
i.v. × 2 + oral
to month 3
TAC, MMF 0 87.5/100
Ciancio49
Single center
Living donor
N = 38
Median 47M rATG 1 mg/kg × 7 i.v. × 3 + oral
ongoing
TAC MMF 0 100/100
ALEM
0.3 mg/kg × × 2
i.v. × 2 + oral
(≤day 7)
TAC 50% MMF 7.7 92.3/92.3
DAC 1 mg/kg × 5 i.v. × 3 + oral
ongoing
TAC MMF 8.3 100/100
ALEM, alemtuzumab; BAS, basiliximab; BPAR, biopsy-proven acute rejection; DAC, daclizumab; EC-MPS, enteric-coated mycophenolate sodium;
IL-2RA, interleukin 2 receptor antagonist; i.v., intravenous; MMF, mycophenolate mofetil; rATG, rabbit antithymocyte globulin; TAC, tacrolimus.
a At end of study (see study duration in column 3).
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c p = 0.003.
ncidence of BPAR was low (14% with sirolimus/MMF, 9% with
sA/MMF) and more  than 80% of patients remained steroid-
ree at month 12. Steroid withdrawal around month 6 thus
ppears feasible under rATG induction with or without CNI
herapy, when high-risk patients are excluded.
igh-immunological  risk  patients
teroid-free immunosuppression is less frequently attempted
n high-risk patients, and data are limited (Table 3). Two
etrospective single-center studies in African-American popu-
ations have assessed outcomes following rATG induction with
.v. steroids to day 4, both with a maintenance regimen of
acrolimus combined with either sirolimus or MMF.43,53 The
ne-year rates of BPAR in both series were acceptable for this
igh-risk group (13–14%), and graft and patient survival was
xcellent, but ﬁrm conclusions cannot be drawn in the absence
f prospective trials. One small randomized trial (n = 21) selec-
ively recruited high-immunological risk patients (PRA >20%
r repeat transplantation).55 The treatment regimens com-
rised alemtuzumab (a single dose of 30 mg)  with tacrolimus
nd no steroids, or rATG (total dose 6 mg/kg) with tacrolimus,
MF,  and steroids to day 5. In this small series, the rate of BPAR
t a median of 12.4 months was 18.2% with alemtuzumab and
7.5% with rATG, while graft survival rates were 85.7% and
7.5%, respectively.55 These relatively high rates of rejection
uggest that steroid avoidance may not be a favorable option in
igh-risk individuals unless there is a speciﬁc clinical impera-
ive. None of these studies employed Luminex® technology todeﬁne the immunological risk pre-transplant, however, which
makes any conclusion uncertain.
Steroid  minimization  and  risk  of  recurrence  of
glomerular  diseases
The advantages of steroid avoidance also have to be balanced
against the risk of recurrence of certain glomerulopathies.
In particular, several retrospective studies have shown that
recurrence of IgA nephropathy is reduced in the presence
of long-term steroid therapy. Among them, Clayton et al.58
analyzed data from the Australia and New Zealand Dialysis
and Transplant Registry (ANZDATA) from 1521 adult recipi-
ents of a ﬁrst kidney transplant in whom kidney failure was
due to biopsy-proven IgA nephropathy. After adjustment for
various confounding variables, steroid use was strongly asso-
ciated with a reduced risk of IgA nephropathy recurrence
(HR 0.50, 95% CI 0.30–0.84). Only 9% of patients in the study
population received depleting induction therapy. Kukla et al.
observed that steroid avoidance may be associated with a
higher rate of recurrent glomerulopathy but found no appar-
ent increase in the risk of graft loss in patients treated with
rATG induction coupled with maintenance therapy compris-
ing tacrolimus and an antimetabolite.59 Von Visger et al.60recently showed similar results in a cohort of 124 patients,
in which 91% of patients in the steroid-free group received
lymphocyte-depleting induction. Although the mechanisms
involved have not been elucidated, steroid avoidance would
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Table 3 – rATG or alemtuzumab induction with steroid avoidance in high-risk or pediatric kidney transplant populations.
Study Population, N Study
duration
Induction  Steroids Maintenance BPAR (%) Graft/patient
survival (%)a
High immunological risk
Haririan53
Single center
Retrospective cohort study
African-American
N = 73
12M rATG  1.5 mg/kg
Mean 4.3 doses
i.v.  to day 4 TAC or SRL,
MMF
13  100/–
rATG 1.5 mg/kg
Mean 7.1 doses
i.v.  + oral ongoing 15 97/–
Zeng54
Single center
Retrospective
African-American
N  = 57
12M  rATG 1.5 mg/kg × 4 i.v. to day 4 TAC or SRL, MMF 14 96/98
Thomas55
Single center
Randomized
High  riskb
N = 21
Median
12.4M
Alemtuzumab
30  mg × 1
i.v. × 1 TAC 18.2 85.7/100 (1 year)
rATG 1.5 mg/kg × 4 i.v. + oral to day 5 TAC, MMF 37.5 87.5/87.5 (1 year)
Children
Chavers3
Single center
Prospective matched controls
Age  7.8–18
N = 60
2Y rATG  1.5 mg/kg × 5–7 i.v. to day 5 CSA, MMF 19 86/95c
rATG
1.5 mg/kg × 6–15
Oral  steroids
ongoing
CSA, AZA 31 90/97c
Li56
Single center
Retrospective control group
rATG: High risk
DAC: Low-risk Mean ∼14Y
N = 26
Mean 13M rATG 1.5 mg/kg × 6 i.v. to day 6 TAC, MMF 0 100/–
DAC to M6 None TAC, MMF 0 100/–
Wittenhagen57
Single center
Retrospective
Age  1.1–14.9Y
N = 65
≤10Y  ATG to 1999 then
rATG 1.25 mg/kg
5–10 days
None  CSA to 1995,
CSA/MMF to 2004,
TAC/MMF to 2009
9 (1 year) 71/93 (10 years)d
AZA, azathioprine; BPAR, biopsy-proven acute rejection; CSA, cyclosporine; DAC, daclizumab; i.v., intravenous; MMF, mycophenolate mofetil; rATG, rabbit antithymocyte globulin; SRL, sirolimus; TAC,
tacrolimus.
a At end of study (see study duration in column 3) unless otherwise stated.
b Panel reactive antibodies >20% or retransplantation.
c Signiﬁcantly improved growth in steroid-free group (mean standard height deviation score −0.9 versus −1.9 [p = 0.003]). Body mass index was similar in both groups.
d Signiﬁcantly improved growth after transplantation (mean standard height deviation score increased from −1.7 to −1.1 [p = 0.007]). Body mass index remained stable.
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ot appear advisable in kidney transplant patients in whom
idney failure was caused by IgA nephropathy.
In other types of glomerular diseases with risk of
ecurrence, such as focal segmental glomerulosclerosis, mem-
ranoproliferative glomerulonephritis or lupus nephritis, for
hich steroids are used as part of the treatment strategy in
ative kidneys, some centers tend to maintain steroids in the
mmunosuppressive protocol after transplantation even in the
bsence of relevant studies.
teroid  minimization  in  pediatric  patients
teroid-sparing strategies are of particular interest in chil-
ren. Randomized trials of steroid avoidance in pediatric
opulations under lymphocyte-depleting induction have not,
owever, been carried out to date. In a single-center prospec-
ive study, Chavers et al. used rATG induction at a relatively
igh dose (1.5 mg/kg for between ﬁve and seven doses) with i.v.
teroids to day 5, with CsA and MMF  as maintenance therapy3
Table 3). The rate of BPAR (19% at two years) was accept-
ble and, importantly, children given the rATG/steroid-free
egimen showed signiﬁcantly improved growth compared to
atched controls given oral steroid therapy (mean standard
eight deviation score −0.9 versus −1.9 in controls; p = 0.003).
ther steroid-related effects (body mass index, lipid proﬁle,
lood pressure) were unaffected although leukopenia was
educed (p = 0.02) and there were fewer Epstein-Barr infections
n the steroid-free arm (p = 0.04).3 Li et al., in a single-center
etrospective study, achieved a 0% rate of BPAR at a mean
f 13 months post-transplant when a relatively high dose of
ATG was employed (total dose 9 mg/kg) with no oral steroids,
acrolimus and MMF,  but growth data were not reported and
here was no comparison versus a steroid-treated cohort.
astly, a retrospective single-center study by Wittenhagen
t al. has described a low rate of BPAR (9% at one year)
n children given lymphocyte-depleting induction (primarily
ATG) with different maintenance regimens.57 Use of deplet-
ng induction in a steroid-avoidance regimen using standard
aintenance therapy seems adequate to prevent rejection in
hildren following kidney transplantation, and merits a more
igorous examination.
teroid-  and  CNI-avoidance  regimens
 small number of trials have investigated novel immuno-
uppressive regimens that avoid both steroids and CNI
herapy.61–63 Ferguson and colleagues randomized 89 kid-
ey transplant recipients at low or moderate immunological
isk to one of three groups: the costimulation blocker belat-
cept with MMF,  belatacept with sirolimus, or tacrolimus
ith MMF.62 All patients received rATG induction (total dose
 mg/kg) with i.v. steroids to day 4 post-transplant and no
ral steroids. At one year, rates of BPAR were acceptable with
elatacept and MMF  (14%), but lower and similar in the belat-
cept/sirolimus group (4%) and the control arm (3%). More
atients in the conventional tacrolimus/MMF group remained
teroid-free at month 12, however (93% versus 73% or 77% in
he belatacept group). So while promising, a CNI-free strategy(5):469–480 477
may not be optimal for achieving steroid-free immunosup-
pression even with lymphocyte-depleting induction. Other
small trials have also pointed to low or acceptable rates
of BPAR when alemtuzumab induction is used to support
CNI-free and steroid-free therapy,61,63 one of which achieved
highly minimized immunosuppression by giving bone mar-
row infusions,63 but such regimens are not currently used in
routine practice.
Discussion
The literature contains few direct comparisons of steroid
minimization regimens versus conventional steroid treatment
in kidney transplant patients receiving lymphocyte-depleting
induction. Studies are typically relatively small, with limited
follow-up periods, and to date, the occurrence of de novo anti-
bodies and antibody-mediated rejection is undocumented.
Nevertheless, the available data show that the risk of acute
rejection is low when rATG induction is given to support
steroid-free regimens after kidney transplantation, at least for
the ﬁrst one to two years post-transplant. In the US, it is com-
mon practice to use rATG and stop steroids by day 7, and this
appears to be a reasonable approach that does not increase
the risk of rejection. In contrast, rejection may be more  likely
under IL-2R antagonist induction using a steroid-avoidance
regimen. Induction with alemtuzumab appears effective in
supporting steroid-free immunosuppression, although it is
not licensed for use in solid organ transplant recipients. For
patients at high immunological risk, the limited data avail-
able suggest that steroid minimization may not be advisable
even with depleting induction therapy. The availability of
single-antigen bead technology, permitting more  precise mea-
surement of anti-HLA antibodies, may enable more  accurate
identiﬁcation of high-risk individuals and feasibly, expand the
pool of patients considered candidates for steroid minimi-
zation.
In children, non-randomized studies indicate that deplet-
ing induction with standard maintenance therapy effectively
prevents acute rejection with steroid avoidance, an encour-
aging ﬁnding given the growth inhibition associated with
chronic steroid administration. More ambitious regimens have
been attempted which include both steroid avoidance and CNI
avoidance, of which depleting induction with maintenance
therapy comprising belatacept and sirolimus appears the most
promising, but currently can be regarded as an experimental
approach.
There is some suggestion that steroid-associated side
effects such as dyslipidemia and weight gain are lower with
steroid-free immunosuppression, but this has not been shown
to translate to an improvement in hard clinical endpoints.
Given the lack of strong evidence in this ﬁeld, no strong con-
clusions can be made.
Early steroid therapy with subsequent withdrawal (i.e. later
than the ﬁrst one or two weeks post-transplant) may be pos-
sible without additional risk of BPAR in patients who  have
received rATG induction, but while encouraging the data are
too sparse for ﬁrm conclusions. Where late steroid withdrawal
is attempted (months 3 to 6 post-transplant), it seems prefer-
able to employ tacrolimus-based immunosuppression over
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CsA. Overall, the effectiveness of steroid avoidance regimens
in this setting is better documented than subsequent with-
drawal strategies.
In summary, there is a suggestion that steroid avoidance
is beneﬁcial for patients after renal transplantation, with the
potential to avoid or reduce steroid-related comorbidities.
Whilst the limited literature seems to indicate that deplet-
ing induction therapy could be the treatment of choice for
steroid minimization and avoidance in kidney transplanta-
tion, the results of prospective randomized, controlled studies
are eagerly awaited.50
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